gene therapy

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics Inc (NASDAQ: ONCE) Luxturna, the first gene therapy in the U.S., has been approved by the Food and Drug Administration. The gene therapy is intended to treat a rare, inherited retinal disease that could possibly cause blindness. U..

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

Novartis AG (NYSE: NVS) is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The U.S. Food and Drug Administration will ask a panel of advisers to focus on the safety of ..